IBS008738
目录号 : GC65951IBS008738 是一种有效的 TAZ 激活剂。IBS008738 稳定C2C12 细胞中的 TAZ,增加未磷酸化的 TAZ 水平,增强 MyoD 与肌细胞生成素启动子的结合,上调 MyoD 依赖性基因转录,并与肌肉生长抑制素竞争。IBS008738 增强 C2C12 细胞的肌生成并促进肌肉损伤模型中的肌肉修复。
Cas No.:385425-03-6
Sample solution is provided at 25 µL, 10mM.
IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model[1][2].
IBS008738 (0, 24, 48, 72 h) enhances TAZ expression, with a peak at 24 h[1].
IBS008738 (10 μM; 0, 24, 72 h) enhances mRNAs of myogenic markers but not of myofusion markers[1].
IBS008738 (10 μM; 24h) enhances mRNAs of IL-10 in C2C12 cells[2].
Western Blot Analysis[1]
Cell Line: | C2C12 cells |
Concentration: | |
Incubation Time: | Treated for 0, 24, 48, 72 h under differentiation conditions after 24 h under growth conditions. |
Result: | Enhanced TAZ expression, with a peak at 24 h. |
RT-PCR[1]
Cell Line: | C2C12 cells |
Concentration: | 10 μM |
Incubation Time: | 0, 24, 72 h under differentiation |
Result: | Enhanced mRNAs of myogenic markers but not of myofusion markers. |
IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles[1].
IBS008738 (30 μM, 100 μL) prevents Dexamethasone-induced muscle atrophy[1].
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI)[2].
Animal Model: | Six-week-old female BALB/cByJ mice[1] |
Dosage: | 3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS) |
Administration: | Injected into the tibialis anterior (TA) muscle of mice under anesthesia. |
Result: | Facilitated muscle repair in Cardiotoxin-injected muscles. |
Animal Model: | Six-week-old female BALB/cByJ mice[1] |
Dosage: | 30 μM (100 μL) |
Administration: | Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13. |
Result: | Prevented Dexamethasone-induced muscle atrophy. |
Cas No. | 385425-03-6 | SDF | Download SDF |
分子式 | C22H22N4O2 | 分子量 | 374.44 |
溶解度 | DMSO : 50 mg/mL (133.53 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6707 mL | 13.3533 mL | 26.7065 mL |
5 mM | 0.5341 mL | 2.6707 mL | 5.3413 mL |
10 mM | 0.2671 mL | 1.3353 mL | 2.6707 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet